This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Damaraju VL, Sawyer MB, Mackey JR, Young JD, Cass CE . Human nucleoside transporters: biomarkers for response to nucleoside drugs. Nucleosides Nucleotides Nucleic Acids 2009; 28: 450–463.
Galmarini CM, Thomas X, Calvo F, Rousselot P, Rabilloud M, El Jaffari A et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 2002; 117: 860–868.
Galmarini CM, Thomas X, Calvo F, Rousselot P, El Jafaari A, Cros E et al. Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res 2002; 26: 621–629.
Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 2005; 93: 1388–1394.
Adams DJ, Sandvold ML, Myhren F, Jacobsen TF, Giles F, Rizzieri DA . Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101 M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leuk Lymphoma 2008; 49: 786–797.
Bergman AM, Kuiper CM, Voorn DA, Comijn EM, Myhren F, Sandvold ML et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 2004; 67: 503–511.
Jin G, Matsushita H, Asai S, Tsukamoto H, Ono R, Nosaka T et al. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. Biochem Biophys Res Commun 2009; 390: 1001–1006.
Adema AD, Laan AC, Myhren F, Fichtner I, Verheul HM, Sandvold ML et al. Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel. Int J Oncol 2010; 36: 285–294.
Galmarini CM, Myhren F, Sandvold ML . CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br J Haematol 2009; 144: 273–275.
Dueland S, Aamdal S, Lind MJ, Thomas H, Sandvold ML, Gaullier JM et al. Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study. Acta Oncol 2009; 48: 137–145.
Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113: 4179–4187.
Capizzi RL, White JC, Powell BL, Perrino F . Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Semin Hematol 1991; 28: 54–69.
Riva-Lavieille C, Ressayre C, Barra Y, Carcassonne Y, Iliadis A . Calculation of individual dosage regimen of cytosine arabinoside (ara-C) based on metabolite levels in leukemic cells. Ther Drug Monit 1994; 16: 375–379.
Burke AC, Giles FJ . Elacytarabine - lipid vector technology overcoming drug resistance in acute myeloid leukemia. Expert Opin Investig Drugs 2011; 20: 1707–1715.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
FJ Giles, N Vey, D Rizzieri and S O'Brien have received research funding from Clavis Pharma. TF Jacobsen, S Hagen and B Nilsson are/were Clavis Pharma employees.
Rights and permissions
About this article
Cite this article
Giles, F., Vey, N., Rizzieri, D. et al. Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies. Leukemia 26, 1686–1689 (2012). https://doi.org/10.1038/leu.2012.1
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.1
This article is cited by
-
Novel Therapeutics in Acute Myeloid Leukemia
Current Hematologic Malignancy Reports (2014)
-
Developmental Therapeutics in Acute Myelogenous Leukemia: Are There Any New Effective Cytotoxic Chemotherapeutic Agents Out There?
Current Hematologic Malignancy Reports (2013)